These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34289749)

  • 81. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 83. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Venat-Bouvet L; Cany L; Catala S; Khayat D; Gambotti L; Pauporté I; Faure-Mercier C; Paget-Bailly S; Henriques J; Grouin JM;
    Lancet; 2019 Jun; 393(10191):2591-2598. PubMed ID: 31178155
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity.
    Ding X; Gu W; Zhong Y; Hao X; Liu J; Xia S; Luo L; Chen M; Zhang C
    EBioMedicine; 2020 Oct; 60():102996. PubMed ID: 32950002
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
    Jaques R; Xu S; Matsakas A
    Histol Histopathol; 2020 Oct; 35(10):1059-1075. PubMed ID: 32323293
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
    Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
    Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Physicochemical and biological characterization of a biosimilar trastuzumab.
    López-Morales CA; Miranda-Hernández MP; Juárez-Bayardo LC; Ramírez-Ibáñez ND; Romero-Díaz AJ; Piña-Lara N; Campos-García VR; Pérez NO; Flores-Ortiz LF; Medina-Rivero E
    Biomed Res Int; 2015; 2015():427235. PubMed ID: 26075238
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
    Yin O; Xiong Y; Endo S; Yoshihara K; Garimella T; AbuTarif M; Wada R; LaCreta F
    Clin Pharmacol Ther; 2021 May; 109(5):1314-1325. PubMed ID: 33118153
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
    Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
    Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study.
    Audran R; Chtioui H; Thierry AC; Mayor CE; Vallotton L; Dao K; Rothuizen LE; Maghraoui A; Pennella EJ; Brunner-Ferber F; Buclin T; Spertini F
    Sci Rep; 2024 Jun; 14(1):12872. PubMed ID: 38834577
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Trastuzumab Charge Variants: a Study on Physicochemical and Pharmacokinetic Properties.
    Torkashvand F; Mehranfar M; Rashidi Gero M; Jafarian P; Mirabzadeh E; Azarian B; Sardari S; Vaziri B
    Iran Biomed J; 2023 Mar; 27(2 & 3):108-16. PubMed ID: 37070702
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies.
    Reijers JA; van Donge T; Schepers FM; Burggraaf J; Stevens J
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1343-1352. PubMed ID: 27515979
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
    Goyal P; Vats B; Subbarao M; Honnappa CG; Kabadi P; Rohil S; Bera A; Mehta GR; Pai H; Adhikari L; Tagore R; Sharma S; Venkatachala R; Nair P; Annegowda S; Sahu A; Trivedi S; Shastri N; Gokhale Y; Thomas R; Thakur A; Mohan D; Rao K U; Melarkode R; Ullanat R
    Expert Opin Biol Ther; 2022 Feb; 22(2):271-298. PubMed ID: 34465264
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
    Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
    Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
    Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
    Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
    Goyal P; Iyer J; Adhikary L; Vats B; Kabadi P; Pai H; Ranayhossaini D; Gouda S; Subbarao M; Mehta G; Saha A; Bera A; Sahu A; Kaur M; Singh A; Marwah A; Reddy Moole PK; Smith J; Melarkode R; Ullanat R
    Future Med Chem; 2021 Sep; 13(18):1531-1557. PubMed ID: 34289749
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.